This FTSE 100 growth stock could be a better buy than AstraZeneca plc

AstraZeneca plc (LON: AZN) is a popular healthcare stock among UK investors. But is this FTSE 100 (INDEXFTSE:UKX) joint replacement specialist a better buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In terms of powerful long-term investment themes, it doesn’t get much bigger than the world’s ageing population. We’re getting older as a global population. Indeed, the World Bank believes that by 2030, the average global life expectancy will rise to 85, up from 71 in 1970. Furthermore, the National Institute on Aging estimates that the number of people aged 65 or older will grow to 16% of the global population by 2050, up from 8% now.

Demand for healthcare

It’s no secret that as we age, our demand for healthcare rises. As a result, stocks such as AstraZeneca (LSE: AZN) represent a popular way for investors to play the theme. But is AstraZeneca the best way to do this? I’m not so sure.

Revenues at the pharma giant have been trending downwards for several years now. Indeed, after reporting revenue of $33.6bn in FY2011, last year it was just $23bn. City analysts expect a further drop this year, to $21.6bn. Furthermore, while AstraZeneca’s dividend yield of 4.2% looks attractive, I’m not convinced the current payout is sustainable. With sales falling, and dividend coverage low, future payments are far from certain, in my opinion.

So how else can investors play the ageing population/healthcare theme? One angle that looks quite compelling could be joint replacements.

Our bodies can’t cope

My grandfather recently passed away at the grand old age of 95. Amazingly, at that age, he was still quite mentally sharp. In fact, one of the last conversations I had with him was regarding the benefits of dividend stocks! However, his body, was a different matter. As a keen golfer who had enjoyed the game for over 70 years, his body was a mess. His knees, hips and shoulders had all given up on him, and he’d needed joint replacement surgery multiple times to keep functioning.

It’s a common problem. In England and Wales alone, there are approximately 160,000 hip and knee replacement procedures performed each year. Surgery techniques and technologies have come a long way in recent years, allowing more patients to consider treatment sooner and enjoy a better quality of life. Can investors capitalise on this trend? Absolutely. Take a look at FTSE 100-listed Smith & Nephew (LSE: SN).

This is a specialist in joint replacement systems for knees, hips and shoulders, and with operations all across the world, including emerging markets, it looks well-placed to benefit as the world’s population gets older and more fragile.

Revenue at the £12.3bn market cap company has been ticking up at a slow but steady rate in recent years, hitting $4.7bn last year. A Q3 trading update released this morning, revealed further progress, with revenue up 3% on both a reported and underlying basis. Growth in established markets was 1% while emerging markets growth was 9%. The company stated that it would be reviewing its cost base to further simplify and improve its operating model, and that the full-year outlook would be at the lower end of the guidance range.

Smith & Nephew looks to be a high-quality company, capable of generating strong operating margins, an excellent return on equity, and attractive dividend growth. As such, I see a great deal of long-term potential here. The shares are a little pricey on a forward P/E ratio of 20.7, however I think that valuation is justified, given the growth prospects on offer.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »